cancer immunotherapy

Nanoparticle-coated bacteria carry cancer-derived proteins to dendritic cells, enabling the immune system to launch a response in a mouse model.

Because most people are vaccinated against tetanus as children, delivering benign bacteria carrying a tetanus antigen into pancreatic tumors makes them visible to memory cells in the immune system, researchers report.

When coated with positively charged particles, the bacteria shuttled antigens out of tumors and activated the immune system, a study finds.

Specialized immune cells generated in vivo reduce cardiac scar tissue in mice, a new study shows.

Several research groups have found that Toxoplasma gondii infection can ramp up antitumor immune responses in mice. Can the single-cell parasite be used to develop safe treatments for humans?

The binding of histamine with one of its receptors within the tumor environment makes cancer cells more resistant to immunotherapy, according to a new study. Blocking that binding could improve responses to treatment.

In a small clinical study, focusing ultrasound beams on tumors in patients’ brains helped open the blood-brain barrier to facilitate drug delivery.

Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.

The results from two Phase 1 trials bolster the case that the gut microbiome plays a role in response to the drugs.

When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.

Meet some of the people featured in the July/August 2020 issue of The Scientist.

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

There’s a new cell-based cancer immunotherapy on the block.